首页> 外文期刊>Journal of clinical laboratory analysis. >Change of miRNA expression profiles in patients with knee osteoarthritis before and after celecoxib treatment
【24h】

Change of miRNA expression profiles in patients with knee osteoarthritis before and after celecoxib treatment

机译:在Celecoxib治疗前后膝关节骨关节炎患者miRNA表达谱的变化

获取原文
获取原文并翻译 | 示例
           

摘要

Background This study aimed to investigate the change of circulating miRNA expression profiles in knee osteoarthritis (OA) patients before and after celecoxib treatment. Methods Two hundred and eighteen knee OA patients underwent celecoxib treatment for 6 weeks were enrolled. Plasma samples were obtained at baseline (W0) and at W6, and treatment efficacy were assessed by WOMAC index. In the exploration stage, miRNA expression profiles in plasma before and after treatment from 6 patients were detected by microarray. Subsequently, in the validation stage, 10 top differentially expressed miRNAs (DEMs) after and before treatment in microarray were further validated in all 218 patients by qPCR. Results In the exploration stage, patients after treatment could be distinguished from them before treatment by miRNAs expression profiles by PCA plot and heatmap analysis, and 45 up-regulated and 48 down-regulated miRNAs were identified by volcano plot. In the validation stage, miR-126-5p and miR-320a levels increased at W6 compared to W0, while miR-155-5p and miR-146a-5p levels decreased. WOMAC pain/stiffness/physical function scores were all decreased at W6 compared to W0, and 71% of patients achieved clinical response. The increase of miR-126-5p expression (W6-W0) in clinical responders was much larger compared to nonclinical responders. And miRNA-320a level declined in nonclinical responders while increased in clinical responders. Conversely, miRNA-146a-5p level increased in nonclinical responders while decreased in clinical responders. Conclusion Circulating miRNA expression profiles act as important roles in knee OA patients underwent celecoxib treatment, and miR-126-5p, miR-320a as well as miR-146a-5p might correlate with treatment response to celecoxib.
机译:背景技术本研究旨在探讨Celecoxib治疗前后膝关节骨关节炎(OA)患者循环miRNA表达谱的变化。方法有二百八八膝核糖患者接受塞克西布治疗6周的治疗。在基线(W0)中获得等离子体样品,并在W6处获得,并通过Womac指数评估治疗疗效。在勘探阶段,通过微阵列检测来自6例患者的血浆中的miRNA表达谱。随后,在验证阶段,在通过QPCR的所有218名患者中进一步验证了在验证阶段和之前和之前的10个顶部差异表达的miRNA(DEM)。结果在勘探阶段,治疗后的患者可以通过PCA图和热映射分析治疗前与它们进行治疗,并通过火山图鉴定45个上调和48个下调的miRNA。在验证阶段,与W0相比,MIR-126-5P和MIR-320A水平在W6上增加,而MIR-155-5P和MIR-146A-5P水平降低。与W0相比,W6的WOMAC疼痛/刚度/物理功能分数均降低,71%的患者取得了临床反应。与非临床响应者相比,临床响应者MiR-126-5P表达(W6-W0)的增加要大得多。在临床响应者中,非临床响应者的miRNA-320A水平下降。相反,非临床响应者的miRNA-146a-5p水平增加,同时在临床响应者中降低。结论循环miRNA表达谱在膝关节OA患者接受锡克罗克西布治疗的重要作用,MIR-126-5P,MIR-320A以及MIR-146A-5P可能与对Celecoxib的治疗反应相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号